What question did this study set out to answer?

This research aims to evaluate the SLE-DAS responder index as a reliable outcome measure in SLE trials.

April 10, 2026

SLE-DAS responder index: a novel outcome measure with high performance for physician and patient outcomes in anifrolumab phase 2-3 trials

Key Points

This research aims to evaluate the SLE-DAS responder index as a reliable outcome measure in SLE trials.
Assessment of the SLE-DAS RI in phase 2-3 trials of anifrolumab.
Comparison of SLE-DAS RI with other efficacy endpoints.
Evaluation of improvements in patient-reported outcomes.
SLE-DAS RI demonstrates robust performance as an efficacy endpoint.
Associated with sustained disease control over time.
Facilitates accurate identification of meaningful outcomes in trial design.

Abstract

The SLE-DAS RI is a robust efficacy end point in SLE trials, associated with sustained disease control and meaningful improvements in patient-reported outcomes. SLE-DAS also enables accurate identification of MSDA, supporting its broader utility in trial design.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Diogo Jesus

University of Beira Interior

Carla Henriques

Polytechnic Institute of Viseu

Ana Matos

Digital Equipment (Germany)

Journals

Lara D. Veeken

Actions

Institutions

University of Padua

University of Coimbra

University of Beira Interior

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

SLE-DAS responder index: a novel outcome measure with high performance for physician and patient outcomes in anifrolumab phase 2-3 trials

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study